50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Relmada Therapeutics (RLMD) rose 61.1% to $7.17 on 92% response rate data, with $2.3B peak sales projection. Xenon's epilepsy drug and Relmada's bladder cancer treatment posted strong efficacy data, clearing major regulatory hurdles and positioning both for commercialization. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but follow major news that has led investors to re-rate each stock. Clinical data results point to a brighter future ahead for both Xenon and Relmada. Azetukalner Clears a Major Hurdle for Xenon The big news for XENE hit Monday morning, when Xenon announced that its lead epilepsy drug, azetukalner, met the primary endpoint in the Phase 3 X-TOLE2 study for focal onset seizures. The result: a 53.2
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics (RLMD) was given a new $10.00 price target by Mizuho.MarketBeat
- Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026GlobeNewswire
- A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 11/13/25 - Miss
RLMD
Sec Filings
- 3/9/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- RLMD's page on the SEC website